Browse every story filed under this topic, curated from trusted publishers around the world.
Arcera and Fosun sign MoU for neuroscience innovation
Arcera Life Sciences and Fosun Pharma have signed an MoU for a strategic long-term collaboration in the global life sciences industry.
Read full story →With ‘lessons learned,’ Kite prepares to hit the ground running as next-gen CAR-T decision looms
After recalibrating its production strategy in the late 2010s to help meet the realities of the CAR-T market, Gilead Sciences’ …
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch …
Europe’s pharma industry risks lagging behind US and China, says German drugmaker
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
Pharma Meets AI Conference 2026: AI governance shifts to embedded practice
AI capabilities within pharma are evolving from add-on to an arm of core business demanding overhauled AI governance.
Pharma Meets AI Conference 2026: AI in pharma begins delivering measurable ROI
AI tools which slash time spent on administration prove their worth and free up pharma workers for higher value tasks.
Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon
Already the largest biopharma company in India, generics powerhouse Sun Pharma has doubled in size with its acquisition of women’s …
Sun Pharma to acquire Organon for $11.75bn
Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in …
Ascletis completes subject enrolment in Phase II ASC3 trial
Ascletis Pharma has completed subject enrolment in its 13-week US Phase II study of ASC30 as a treatment for type …
VC Firm Kurma Partners Closes €215M Fund in Pursuit of ‘Disruptive Therapeutic Solutions’
Kurma Partners’ new fund is the venture capital firm’s fourth and largest. Previous Kurma investments have led to exits that …
STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for …
Fierce Pharma Asia—Merck’s PD-1xVEGF data; Zai Lab’s global view; Kailera’s record IPO
Merck & Co. unveiled the much-anticipated first look at its PD-1xVEGF bispecific data. China's Zai Lab is looking to go …
Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs
Avalyn Pharma is hoping to rake in around $181.8 million from an IPO, which the biotech will use to take …
Pharma Meets AI Conference 2026: Key barriers to scaling AI in drug development
Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.
6 big pharma moves
Drugmakers and industry groups are accelerating investments in AI, manufacturing and dealmaking while navigating regulatory and policy shifts. Recent moves …
STAT+: RFK Jr. backs off some MAHA issues
RFK Jr. is backing vaccinations and defending secret deals with pharma companies.
STAT+: Pharmalittle: We’re reading about cheap telehealth visits, pharma withholding meds in Europe, and more
Drugmakers have begun using coupons to discount the cost of telehealth visits with clinicians who can prescribe their drugs
رئيس الوزراء يفتتح توسعات مصنع "أتيكو فارما إيجيبت" بمنطقة السخنة الصناعية
في ختام جولته اليوم بالمنطقة الاقتصادية لقناة السويس، افتتح الدكتور مصطفى مدبولي، رئيس مجلس الوزراء، ومرافقوه، توسعات مصنع "أتيكو فارما …
Calluna concludes patient enrolment in Phase II trial for IPF
Calluna Pharma has concluded patient enrolment ahead of schedule in its global Phase II AURORA clinical trial evaluating CAL101 for …
Merck’s new AI commercial strategy ‘reimagining engagement with HCPs’
Merck & Co.’s $1 billion deal with Google Cloud is seeking to bolster its AI credentials—and the U.S. Big Pharma …
You've seen all articles for #pharma.
Check back
soon
for new stories.